



## **Mylan Announces Final FDA Approval and Immediate Shipment of Zolpidem Tartrate Tablets**

PITTSBURGH, April 23 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Zolpidem Tartrate Tablets, 5 mg and 10 mg. This product is being shipped immediately.

Zolpidem Tartrate Tablets are the generic version of Sanofi-Aventis' Ambien<sup>®</sup> Tablets. Ambien Tablets had U.S. sales of approximately \$2.2 billion for the same strengths for the 12-month period ending Dec. 31, 2006, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit [www.mylan.com](http://www.mylan.com).

SOURCE Mylan Laboratories Inc.

CONTACT: Patrick Fitzgerald or Kris King, both of Mylan Laboratories Inc., +1-724-514-1800

Web site: <http://www.mylan.com>